Notch2 alterations in NSCLC, on the other hand, have been reported to include both activating and inactivating mutations, and, in contrast to what has been observed in Notch1, these alterations are mainly found to be gene amplifications (TCGA, MSKCC, cBioportal (www.cbioportal.org [98,99])), both in ACL and SCC, which could in fact go along with the increased expression observed in patients with advanced NSCLC stage and disease relapse [16]. The gene discussed is NOTCH1; the disease is non-small cell lung carcinoma.